MVA BN human papillomavirus vaccine

Drug Profile

MVA BN human papillomavirus vaccine

Alternative Names: MVA-BN HPV

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator Bavarian Nordic
  • Developer Bavarian Nordic; Janssen
  • Class Cancer vaccines; Papillomavirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Human papillomavirus infections

Most Recent Events

  • 18 May 2016 Preclinical trials in Human papillomavirus infections in USA (unspecified route)
  • 18 Dec 2015 MVA BN human papillomavirus vaccine licensed to Janssen ,, Bavarian Nordic website, May 2016)
  • 18 Dec 2015 Early research in Human papillomavirus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top